Streetbeat News

Revenues

HIW

Highwoods Properties (NYSE:HIW), a REIT focused on urban properties in the Southern US, has seen a shift in analyst sentiment over the past three months, with 4 analysts providing ratings. The average 12-month price target has decreased to $22.5 from $29.25, with individual targets ranging from $18 to $28. Analysts from Morgan Stanley, Truist Securities, B of A Securities, and Mizuho have all lowered their price targets. Despite the lowered targets, Highwoods Props has shown strong financial performance with a revenue growth rate of 0.05%, a net margin of 10.67%, an ROE of 0.91%, and an ROA of 0.37%, although it has a high debt-to-equity ratio of 1.33.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 1:01 pm

LLY

Eli Lilly (NYSE:LLY) has received diverse opinions from 14 analysts over the past quarter, with 3 bullish, 10 somewhat bullish, and 1 indifferent. The average 12-month price target is $643.21, with a high of $722.00 and a low of $535.00, marking a 4.93% increase from the previous average of $613.00. Analysts from firms like Daiwa Capital, Truist Securities, and Morgan Stanley have maintained or raised their ratings and price targets. Eli Lilly, a drug firm focusing on various therapeutic areas, has shown a revenue growth rate of 36.84% as of September 30, 2023, but has below-average net margin, ROE, and ROA, and a high debt-to-equity ratio of 1.8.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 1:00 pm

ADSK

Autodesk (NASDAQ:ADSK) has been the subject of diverse analyst ratings over the past three months, with 12 financial analysts offering varying opinions. The average 12-month price target is $238.33, a slight decrease from the previous $245.00. Analysts have adjusted their ratings and price targets, with some maintaining their positions while others have raised or lowered their expectations. Autodesk's financial performance shows strong revenue growth, net margin, ROE, and ROA, but a high debt-to-equity ratio. The company has over 4 million paid subscribers and operates in various industries.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 1:00 pm

FLT

Analysts have provided mixed opinions on Fleetcor Technologies (NYSE:FLT) with 10 recent ratings ranging from bullish to bearish. The average 12-month price target is $280.0, with a high of $315.00 and a low of $235.00, indicating a slight upward trend. Fleetcor's financials show strong profitability with a high net margin and ROE, but revenue growth lags behind industry peers and debt management poses a challenge with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 1:00 pm

BRNS

Barinthus Biotherapeutics is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford to accelerate the development of the VTP-500 vaccine, aimed at preventing Middle East Respiratory Syndrome (MERS). CEPI will invest up to $34 million in funding for this initiative.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:41 pm

WILC

G. Willi-Food Intl reported a decrease in Q3 earnings to $0.10 per share from $0.16 YoY and a 7.16% drop in sales to $32.40M from $34.90M YoY.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:36 pm

MRK

Merck and Eisai's cancer treatment combination of Keytruda and Lenvima has been publicly listed under drug plans in several Canadian provinces for treating advanced endometrial carcinoma that is not MSI-H or dMMR. This could potentially increase the accessibility and usage of the treatment in Canada, which may have a positive impact on sales.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:12 pm

FLR

LASE

Laser Photonics has received an order for its MarkStar Pro Laser Marking System from the Construction Purchasing Division of Fluor. This order could indicate a growing demand for Laser Photonics' products within the construction industry and may signal potential revenue growth for the company.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:08 pm

OFIX

Orthofix Medical Inc. (NASDAQ:OFIX) announced the publication of new data supporting the use of PEMF stimulation with their SpinalStim device in lumbar spine fusion procedures. The study, published in the International Journal of Spine Surgery, showed successful fusion and significant improvements in patients at risk of pseudarthrosis.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:05 pm

EXAI

SNY

Exscientia announced that Sanofi is expanding their collaboration by adding a new discovery stage program. Exscientia is eligible to receive up to $45M in upfront and preclinical milestone payments, and potentially over $300M in additional milestone payments.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 12:05 pm